Some studies have proposed that the increase in atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and O-GlcNAc can be used as biomarkers of DCM [6–8], as well as the increase in calcium-sensitive receptors in cardiomyocytes and restoration of calcium homeostasis in type II DCM [9]. The gene discussed is NPPA; the disease is familial dilated cardiomyopathy.